{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:00Z","timestamp":1793241420872,"version":"4.5.0"},"reference-count":65,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cutaneous T-cell lymphoma (CTCL) comprises a spectrum of T-cell lymphomas with primary skin involvement. Mycosis fungoides (MF) and Sezary syndrome (SS) are the common subtypes of CTCL in which patients present with widely diverse profiles of skin involvement and varying extents of extracutaneous disease. Patients with early-stage disease have an excellent prognosis and are managed primarily with skin-directed therapies; however, those with advanced-stage MF or SS often require multiple lines and recurrent courses of systemic therapies. Many options are available when considering systemic agents, and it is often challenging to know how to prioritize therapies to address a patient's objective disease and quality of life issues. Appreciating the disease heterogeneity and understanding the patient's overall disease profile (eg, skin, lymph nodes, blood, large cell transformation) serve as a useful framework in aligning therapies that can optimally treat active sites of disease. Tissue or blood biomarkers can be integrated into our process of prioritizing therapies and personalizing management in MF or SS. Multidisciplinary management and optimizing supportive care are additional key elements for a favorable outcome. Appropriate patients with high-risk disease should be considered for allogeneic hematopoietic stem cell transplant.<\/jats:p>","DOI":"10.1182\/hematology.2021000263","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:12:01Z","timestamp":1639120321000},"page":"303-312","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["What factors guide treatment selection in mycosis fungoides and Sezary syndrome?"],"prefix":"10.1182","volume":"2021","author":[{"given":"Youn H.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"16","key":"2021121012070611900_hem2021000263C1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021121012070611900_hem2021000263C2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"issue":"10","key":"2021121012070611900_hem2021000263C3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1159\/000509281","article-title":"Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020","volume":"181","author":"Bobrowicz","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"issue":"18","key":"2021121012070611900_hem2021000263C4","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021121012070611900_hem2021000263C5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428194.2012.711829","article-title":"Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"July","key":"2021121012070611900_hem2021000263C6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study","volume":"133","author":"Dummer","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"2021121012070611900_hem2021000263C7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2021121012070611900_hem2021000263C8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2021121012070611900_hem2021000263C9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"32","key":"2021121012070611900_hem2021000263C10","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10094","key":"2021121012070611900_hem2021000263C11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"2021121012070611900_hem2021000263C12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"2021121012070611900_hem2021000263C13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"29","key":"2021121012070611900_hem2021000263C14","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021121012070611900_hem2021000263C15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bjh.15905","article-title":"Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and S\u00e9zary syndrome","volume":"186","author":"Jothishankar","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2021121012070611900_hem2021000263C16","doi-asserted-by":"crossref","first-page":"100629","DOI":"10.1016\/j.adro.2020.11.014","article-title":"Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and S\u00e9zary syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"2021121012070611900_hem2021000263C17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"2021121012070611900_hem2021000263C18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2021121012070611900_hem2021000263C19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0889-8588(03)00111-4","article-title":"Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma","volume":"17","author":"Demierre","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2021121012070611900_hem2021000263C20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2340\/00015555-3171","article-title":"Health-related quality of life in cutaneous lymphomas: past, present and future","volume":"99","author":"Jonak","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"2021121012070611900_hem2021000263C21","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2021121012070611900_hem2021000263C22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021121012070611900_hem2021000263C23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","article-title":"Low-dose methotrexate for the S\u00e9zary syndrome","volume":"21","author":"Zackheim","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2021121012070611900_hem2021000263C24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ijd.12121","article-title":"Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature","volume":"52","author":"Quaglino","year":"2013","journal-title":"Int J Dermatol"},{"issue":"8","key":"2021121012070611900_hem2021000263C25","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2021121012070611900_hem2021000263C26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J Neurooncol"},{"key":"2021121012070611900_hem2021000263C27","doi-asserted-by":"crossref","article-title":"A phase II trial of reduced dose brentuximab vedotin for cutaneous T-cell lymphoma","author":"Khan","DOI":"10.1002\/hon.123_2880"},{"issue":"suppl 1","key":"2021121012070611900_hem2021000263C28","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/blood-2018-99-118473","article-title":"Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 MAVORIC study in previously treated cutaneous T-cell lymphoma","volume":"132","author":"Bagot","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012070611900_hem2021000263C29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-141041","article-title":"Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial","volume":"136","author":"Musiek","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2021121012070611900_hem2021000263C30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2021121012070611900_hem2021000263C31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaoncol.2016.0004","article-title":"Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous T-cell lymphoma","volume":"2","author":"Martinez-Escala","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"2021121012070611900_hem2021000263C32","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"32","key":"2021121012070611900_hem2021000263C33","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021121012070611900_hem2021000263C34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/PAS.0000000000001041","article-title":"The use of central pathology review with digital slide scanning in advanced-stage mycosis fungoides and S\u00e9zary syndrome: a multi-institutional and international pathology study","volume":"42","author":"Gru","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2021121012070611900_hem2021000263C35","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"32","key":"2021121012070611900_hem2021000263C36","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"2021121012070611900_hem2021000263C37","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2021121012070611900_hem2021000263C38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"33","key":"2021121012070611900_hem2021000263C39","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012070611900_hem2021000263C40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"2021121012070611900_hem2021000263C41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021121012070611900_hem2021000263C42","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jid.2017.11.035","article-title":"Variability in the expression of immunohistochemical markers: implications for biomarker interpretation in cutaneous T-cell lymphoma","volume":"138","author":"Rahbar","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2021121012070611900_hem2021000263C43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cjp2.180","article-title":"Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia\/lymphoma","volume":"7","author":"Fujii","year":"2021","journal-title":"J Pathol Clin Res"},{"issue":"12","key":"2021121012070611900_hem2021000263C44","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase \u00bd study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2021121012070611900_hem2021000263C45","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","article-title":"Pembrolizumab in mycosis fungoides with PD-L1 structural variants","volume":"5","author":"Beygi","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2021121012070611900_hem2021000263C46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ccell.2021.04.018","article-title":"A tumor \u201cpersonality\u201d test to guide therapeutic decision making","volume":"39","author":"Houlahan","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"2021121012070611900_hem2021000263C47","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci"},{"issue":"5","key":"2021121012070611900_hem2021000263C48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"2021121012070611900_hem2021000263C49","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in Sezary syndrome with SIRPalphaFc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2021121012070611900_hem2021000263C50","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/10428194.2019.1594220","article-title":"Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1\/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation","volume":"60","author":"Gomez-Arteaga","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2021121012070611900_hem2021000263C51","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2021121012070611900_hem2021000263C52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"23","key":"2021121012070611900_hem2021000263C53","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021121012070611900_hem2021000263C54","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta- analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2021121012070611900_hem2021000263C55","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"29","key":"2021121012070611900_hem2021000263C56","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021121012070611900_hem2021000263C57","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2021121012070611900_hem2021000263C58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"2021121012070611900_hem2021000263C59","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2021121012070611900_hem2021000263C60","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1080\/10428194.2020.1790555","article-title":"Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma delta T cell lymphomas","volume":"61","author":"Isufi","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2021121012070611900_hem2021000263C61","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"key":"2021121012070611900_hem2021000263C62","doi-asserted-by":"crossref","article-title":"Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis","author":"Mehta-Shah","DOI":"10.1182\/blood-2020-138542"},{"issue":"21","key":"2021121012070611900_hem2021000263C63","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021121012070611900_hem2021000263C64","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2021121012070611900_hem2021000263C65","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/303\/1852064\/303kim.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/303\/1852064\/303kim.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T17:51:31Z","timestamp":1699897891000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/303\/482996\/What-factors-guide-treatment-selection-in-mycosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000263","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}